No differences were found in atrial immunoreactive levels of ACE2 between sham controls, compensated and decompensated CHF, although ACE2 mRNA was significantly higher in compensated in both atria as compared with decompensated subgroup and sham controls (Data not shown). This evidence concerns the gene ACE2 and congestive heart failure.